Finding the right combination antiviral therapy for influenza

The Lancet Infectious Diseases

Volumn 17, Issue 12, 2017, Pages 1221-1222

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; FAVIPIRAVIR; HYPERIMMUNE GLOBULIN; LANINAMIVIR; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; PLACEBO; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UMIFENOVIR; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASIA; DRUG EFFICACY; HUMAN; IC50; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA B; INFLUENZA B VIRUS; MONOTHERAPY; NOTE; PRIORITY JOURNAL; SEASONAL INFLUENZA; SYMPTOM; VIROLOGY; VIRUS SHEDDING; VIRUS STRAIN; COMBINATION DRUG THERAPY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; INFLUENZA, HUMAN; OSELTAMIVIR;

EID: 85029750032     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30537-6     Document Type: Note

References (15)

1. Naesens, L, Stevaert, A, Vanderlinden, E, Antiviral therapies on the horizon for influenza. Curr Opin Pharmacol 30 (2016), 106–115.
2. Hayden, FG, Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 7:suppl 1 (2013), 63–75.
3. Nguyen-Van-Tam, JS, Venkatesan, S, Muthuri, SG, Myles, PR, Neuraminidase inhibitors: who, when, where?. Clin Microbiol Infect 21 (2015), 222–225.
4. Bright, RA, Medina, MJ, Xu, X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005), 1175–1181.
5. Nguyen, HT, Fry, AM, Gubareva, LV, Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 17:part B (2012), 159–173.
6. Okomo-Adhiambo, M, Sleeman, K, Ballenger, K, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2 (2010), 2269–2289.
7. Dunning, J, Baillie, JK, Cao, B, Hayden, FG, on behalf of the International Severe Acute Respiratory and Emerging Infection Consortium. Antiviral combinations for severe influenza. Lancet Infect Dis 14 (2014), 1259–1270.
8. Ison, MG, Gnann, JW Jr, Nagy-Agren, S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8 (2003), 183–190.
9. Duval, X, van der Werf, S, Blanchon, T, et al. Efficacy of oseltamivir–zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med, 7, 2010, e1000362.
10. Beigel, JH, Tebas, P, Elie-Turenne, MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5 (2017), 500–511.
11. Nguyen, JT, Hoopes, JD, Le, MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One, 5, 2010, e9332.
12. Nguyen, JT, Smee, DF, Barnard, DL, et al. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One, 7, 2012, e31006.
13. Seo, S, Englund, JA, Nguyen, JT, et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 18 (2013), 377–386.
14. Beigel, JH, Bao, Y, Beeler, J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis, 2017 published online Sept 22. http://dx.doi.org/10.1016/S1473-3099(17)30537-6.
15. Marjuki, H, Mishin, VP, Chesnokov, AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. J Infect Dis 211 (2015), 249–257.